



FORMULATION, OPTIMIZATION AND IN VITRO EVALUATION OF GASTRORETENTIVE 
MUCOADHESIVE MICROSPHERES OF FUROSEMIDE 
Original Article 
 
SANDEEP KUMAR, ARUN NANDA* 
*
Received: 11 Mar 2016 Revised and Accepted: 20 May 2016 
Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, India 124001 
Email: an_mdu@rediffmail.com    
ABSTRACT 
Objective: The objective of this study was to formulate and evaluate sustained release gastro retentive microspheres of furosemide using 
mucoadhesive polymers. It was expected that gastro retention plus mucoadhesion would contribute to extending the rate of drug release in the 
acidic medium in vitro, thereby projecting this formulation as a potential candidate for improvement of oral bioavailability of furosemide. 
Methods: Mucoadhesive microspheres of furosemide were formulated by ionic gelation method by using two opposite charge mucoadhesive 
polymers (cationic chitosan and anionic sodium alginate). The formulations were optimized by employing 22
Results: The microspheres formed were spherical in shape, and size ranged between 692-815 µm. Drug entrapment efficiency, % mucoadhesion 
and % drug release were ranged between 74.82-84.21 %, 22-43 % and 85.01-94.21 % respectively. DSC analysis revealed that there was no 
incompatibility between drug and excipients. The mechanism of drug release from microspheres followed Hixson-Crowell model. Comparison of 
drug release with marketed formulation (Lasix-40
 factorial design and characterized for 
in vitro evaluation i.e. drug entrapment efficiency, mucoadhesion study, drug release study, swelling study, etc. 
®
Conclusion: This work suggests that gastro retentive mucoadhesive microspheres, an effective drug delivery system for furosemide in improving 
the bioavailability of the drug. 
) demonstrated the sustained release pattern of the gastro retentive mucoadhesive 
microspheres of Furosemide. 
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INTRODUCTION 
Furosemide (FR) is a loop diuretic and chemically related to the 
sulphonamide. It has been chemically described as 4-chloro-2-
[(furan-2-ylmethyl) amino]-5-sulfamoylbenzoic acid. It inhibits 
water reabsorption in the nephron by blocking the sodium-
potassium-chloride cotransporter (NKCC-2) in the thick ascending 
limb of the loop of Henle [1]. Furosemide is widely used in the 
treatment of high blood pressure, edema associated with renal 
disease, nephritic syndrome, cirrhosis of the liver and congestive 
heart failure. The absolute bioavailability of Furosemide 
administered as a 100 mg tablet (equivalent 40 mg of Furosemide) is 
about 60-70 % [2]. FR is absorbed mostly in the stomach and upper 
small intestine, possibly due to its weak acidic properties (pKa 3.9) 
and it has a short half-life (1-2 h) [3]. The narrow absorption 
window of furosemide in the upper part of the GIT, together with its 
improved effect upon continuous drug input, provides a rationale for 
developing a gastro retentive dosage form for this drug [4]. 
Oral delivery of the drug is the most preferable route of drug 
delivery due to the ease of administration, patient compliance, and 
flexibility in the formulations. The major objective of oral controlled 
drug delivery system is to deliver drugs for a longer period of time to 
achieve better bioavailability, which should be predictable and 
reproducible [5]. Several approaches have been designed to retain 
the dosage forms in the stomach.  
These methods include bio adhesive systems, swelling systems, 
expanding systems and floating systems. An oral sustained dosage 
form is particularly useful if the drug is absorbed throughout the GIT 
as the dosage form passes forward releasing the drug in GIT. One of 
the major limiting factor in oral sustained drug delivery is the short 
transit time which makes the drug remain at the absorption site for 
too short time to get absorbed completely from the desired site and 
there is no or little control over release of drug and thus effective 
concentration has to be achieved by multiple dosing. These 
problems can be overcome by the development of gastro retentive 
sustained release dosage forms [6]. Gastro retentive systems can 
remain in the gastric region for several hours and hence significantly 
prolong the gastric residence time of drugs. Prolonged gastric 
retention improves bioavailability, reduces drug waste, and 
improves solubility for drugs that are less soluble in a high pH 
environment. It has applications also for local drug delivery to the 
stomach and proximal small intestines. Gastro retention helps to 
provide better availability of new products with new therapeutic 
possibilities and substantial benefits for patients [7]. 
Mucoadhesive drug delivery systems (MDDS) possess additional 
advantages, such as close contact with the mucosal surface, when 
compared to other approaches. The MDDS provides a high surface to 
volume ratio and longer residence time, resulting in effective 
absorption and increased the bioavailability of the drug. The MDDS 
can also be tailored to adhere to any mucosal tissue in the GIT, 
including those found in the stomach. Thus, the MDDS offers an 
advantage for achieving localized, as well as systemic, controlled 
release of drugs [8]. Mucoadhesive microspheres include 
microparticles and microcapsules (having a core of the drug) of 1–
1000 µm in diameter and consisting either entirely of a bioadhesive 
polymer or having an outer coating of it, respectively. Microspheres, 
in general, have the potential to be used for targeted and controlled 
release drug delivery; but coupling of bioadhesive properties to 
microspheres has additional advantages, e. g., Efficient absorption 
and enhanced bioavailability of the drugs due to a high surface to 
volume ratio, a much more intimate contact with the mucous layer, 
specific targeting of drugs to the absorption site achieved by 
anchoring plant lectins, bacterial adhesions and antibodies, etc. on 
the surface of the microspheres. Bioadhesive microspheres can be 
tailored to adhere to any mucosal tissue including those found in 
eye, nasal cavity, urinary and gastrointestinal tract, thus offering the 
possibilities of localized as well as systemically controlled release of 
drugs. Application of bioadhesive microspheres to the mucosal 
tissues of ocular cavity, gastric and colonic epithelium is used for 
administration of drugs for localized action. Prolonged release of 
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drugs and a reduction in the frequency of drug administration to the 
ocular cavity can highly improve the patient compliance [9]. 
Chitosan, a natural linear bio poly aminosaccharide is obtained by 
alkaline deacetylation of chitin, which is the second abundant 
polysaccharide next to cellulose. Chitin is a straight homopolymer 
composed of β-(1, 4)-linked N-acetyl-glucosamine units while 
chitosan comprises of copolymers of glucosamine and N-acetyl-
glucosamine. Chitosan has one primary amino and two free hydroxyl 
groups for each C6 building unit. Due to the easy availability of free 
amino groups in chitosan, it carries a positive charge and thus, in 
turn, reacts with many negatively charged surfaces/polymers and 
also undergoes chelation with metal ions [10]. 
Alginate is a copolymer, consisting of linear chains of α-L-glucuronic 
acid (G) and β-D-mannuronic acid (M) produced by marine brown 
algae. It is a useful biopolymer to prepare nanocapsules due to its 
good biocompatibility, biodegradability, non-toxicity and 
mucoadhesion properties. Glucuronic acids of alginate have the 
ability to exchange their Na+ion and react with Ca2+
The present study aims to formulate and evaluate sustained-release 
gastro retentive microspheres of Furosemide using mucoadhesive 
polymers. Mucoadhesive microspheres had advantages such as 
efficient absorption and enhanced bioavailability of furosemide 
owing to a high surface to volume ratio, a much more intimate 
contact with the mucus layer and specific targeting to the absorption 
site. Sustained-release microspheres of furosemide would provide 
constant plasma concentration, with the less frequent 
administration and may also decrease the side effects to some 
extent. This could extend its safe administration and improve patient 
compliance.  
. In this reaction, 
the α-L-glucuronic acid groups will connect to each other by these 
divalent cations. Dimerization of alginate chains will also help them 
to join with many other chains which result in a gel network [11]. 
MATERIALS AND METHODS 
Materials 
Furosemide was supplied as gift sample by Brawn Laboratories Ltd, 
Faridabad, India; the following materials were purchased from, 
Sodium alginate (Loba Chemie, Mumbai, India), Chitosan (Bio-Gen 
Extracts, New Delhi, India), Calcium chloride (Loba Chemie, Mumbai, 
India). All other reagents were of analytical grade. 
Drug-excipient compatibility and stability study 
Any interaction between drug and excipients was studied by DSC. 
Accurately weighed a sample of furosemide along with the 
excipients was hermetically sealed in an aluminum crucible. A blank 
hermetically sealed aluminum crucible was used as a reference pan. 
The system was purged with nitrogen gas at a flow rate of 60 
ml/min and heating was done from 40-300 °C [1]. 
Factorial design and selection of optimized formulation 
22 Factorial is the simplest factorial design in which two factors are 
studied at two levels, low and high. First of all amounts of sodium 
alginate and chitosan used were determined from the literature 
study and fixed minimum and maximum amount to be used. Then 
different formulations were designed according to 22
 
 factorial 
designs. These formulations were prepared and tested for 
optimization parameters, i.e., entrapment efficiency, mucoadhesion 
study and release rate study. The amount of drug incorporated in 
each formulation was 1 g. The different formulations were prepared 
according to formula as shown in table 1. 
Table 1: Different formulations according to formula 
Formulation No. Experiment Drug (gram) Sodium alginate (gram) A Chitosan (w/v) B Calcium chloride (w/v) 
1 (1) 1 0.5 (Low) 0.5 % (Low) 3.0 % 
2 A 1 2.0 (High) 0.5 % (Low) 3.0 % 
3 B 1 0.5 (Low) 1.0 % (High) 3.0 % 
4 Ab 1 2.0 (High) 1.0 % (High) 3.0 % 
 
Inserting data in factorial design equations 
Equation (1) for effect of factor A is  
Effect of factor A = 1
2
 [(ab+a)-(b+1)]………. (1) 
Similarly, the effect of factor B is given by equation (2) as follows 
Effect of factor A = 1
2
 [(ab+b)-(a+1)]………. (2) 
If the two factors have interaction between them, then the 
magnitude of interaction can be calculated by the following method.  
The magnitude of the interaction term is then calculated in the same 
way as that of the main factors, i.e. the mean of the results of all 
experiments with a ‘+’ in interaction column minus the mean of all 
those with a ‘-’ in that column. Interaction of A and B can be 
calculated by the following equation (3). 
Magnitude of interaction = 1
2
×[(1+ab)–(a+b)]………….(3) 
If the combined effect of the two factors had been to produce an 
effect greater than that produced by the factor individually, then the 
interaction is said to be synergistic. An interaction which produced a 
decrease is antagonistic. 
Preparation of microspheres 
Formulation of extended-release microspheres was done by using 
ionic gelation method [12]. Sodium alginate, an anionic 
mucoadhesive polymer was used as core material and cross-linked 
with chitosan which was cationic in nature and calcium chloride 
solution. Aqueous insoluble alginate-chitosan-calcium microspheres 
were formed by interaction between two oppositely charged 
polymers and cation exchange between Na+ and Ca2+
Evaluation of microspheres 
. In this 
technique, sodium alginate was dissolved in purified water by 
simply agitating. Then drug was added into sodium alginate solution 
and ultra sonicated for 2 h to form a viscous dispersion. The 
resulting dispersion was added manually dropwise into different 
concentrations of chitosan and calcium chloride (3 %) solution 
through a syringe with a needle of size no. 26 gauge with gently 
stirring. The added droplets were retained in the calcium chloride 
and chitosan for 30 min to complete the curing reaction and to 
produce rigid spherical microspheres. The microspheres were 
collected by decantation, and the microspheres thus separated were 
repeatedly washed with purified water and dried at 45 °C for 12 h. 
The microspheres were evaluated for different parameters as 
described below:  
1. Microencapsulation efficiency 
2. Mucoadhesion study 
3. In vitro drug release 
4. Size distribution analysis 
5. Swelling index study 
6. Selection of mathematical models 
7. Stability study 
Microencapsulation efficiency 
Furosemide content in microspheres was determined by UV-
spectrophotometer (UV-Shimadzu, Japan). 100 mg microspheres 
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were crushed in a glass mortar-pestle, and the powdered microspheres 
were suspended in 100 ml pH 5.8 phosphate buffer. The solution was 
shaken occasionally and kept for 24 h. After 24 h, the solution was 
filtered to obtain a clear solution and the filtrate was analyzed for drug 
content spectrophotometrically at 277 nm [13, 14]. 





For the mucoadhesion study, the use of goat intestinal mucosa had been 
approved by the Institutional Animal Ethics Committee, M. D. University, 
Rohtak with approval number Ph. Sci.-998, dated-08/08/2013. The 
freshly excised pieces of the intestinal mucosa (2×3 cm.) from goat were 
tied onto glass slides using thread. About 50 microspheres were spread 
onto each wet rinsed tissue specimen and immediately thereafter the 
slides were placed into the USP Type II dissolution apparatus containing 
pH 5.8 phosphate buffer operated at 50 rpm. At different time intervals 
up to 8 h the apparatus was stopped, and the numbers of microspheres 
still adhering to the tissue were counted. The percentage mucoadhesion 
was calculated [15-17]. 
% Mucoadhesion =  
No. of microspheres adhered
No. of microspheres applied
× 100 
In vitro drug release 
In an ideal situation, an extended release oral dosage form should be 
tested in vitro throughout the entire physiology pH (1-7.8) of the GI 
tract in order to simulate the in vivo conditions. The in vitro 
dissolution studies were performed using USP Type II dissolution 
apparatus at 50 rpm. The dissolution medium was kept in a 
thermostatically controlled water bath maintained at 37 °C±0.5 °C 
and volume of dissolution medium was 900 ml. Dissolution studies 
were carried out up to 8 h. An aliquot (5 ml) was withdrawn at 
specified time intervals, filtered through Whatman filter papers and 
drug content was determined by UV-Spectrophotometer at 277 nm. At 
each withdraw; 5 ml of fresh dissolution medium was replaced into 
the dissolution flask to maintain the sink condition. The phosphate 
buffer of pH 5.8 was used as dissolution media for the purpose of 
testing [18]. Microspheres equivalent to containing 40 mg of drug 
were used for in vitro release study. Dissolution data obtained was 
plotted as cumulative percentage drug release v/s time. 
Size distribution analysis 
Size distribution analysis of microspheres was performed by an 
optical microscope to determine the average size of microspheres. 
The microspheres were dispersed in liquid paraffin, and a drop off 
above dispersion was put on a glass slide and observed under a 
microscope. The diameter of 50 microspheres was determined using 
calibrated eyepiece micrometer and stage micrometer [14, 19]. The 
average diameter was calculated using the following formula:  




n= number of microspheres, d= diameter of microspheres. 
Swelling index study 
The swelling study was carried for the prepared microspheres. The 
pre-weighed microspheres were immersed in 100 ml of medium (pH 
5.8 phosphate buffer) and maintained at temperature 37 °C±0.5 °C 
for 6 h of the study period. At predetermined time intervals (1, 2, 3, 
4, 5 and 6 h); the swollen microspheres were removed from the 
solution, immediately wiped with a paper towel to remove droplets 
of surface and weighed. The swelling index (S. I.) was calculated 
according to the following formula: [13, 17] 




Where, W0 = initial weight of dry microspheres, and Wt
Selection of mathematical models 
Several theories/kinetics models have been published, to elucidate 
the resulting drug release kinetics from extended release dosage 
forms. There are several models to represent the drug dissolution 
profiles where drug release is a function of time (t) related to the 
amount of drug dissolved from pharmaceutical dosage system.  
The drug release data was modeled into various rate equations 
including zero order, first order, Higuchi equation, Hixson-Crowell 
plot and Peppas-Korsemeyer equation. The best-fit model was 
selected on the basis of greatest R
 = weight of 
swollen microspheres at time t. 
2 value [20, 21]. 
Stability study 
Stability studies from an integral part of the formulation 
development process as the stability of the active components is a 
major criterion in determining its acceptance. In order to assess the 
stability of drug product, accelerated stability studies were 
conducted for the optimized batch of model drug microspheres. 
Microspheres were stored in glass vials for one month at storage 
condition 40 °C±2 °C/75 % RH±5 %. The products charged for 
stability are to be monitored for the physical appearance, assay, and 
dissolution [22]. 
In vitro release study of optimized formulation vs marketed 
formulation 
Dissolution studies were performed for a marketed immediate 
release tablet formulation (Lasix, 40®
The mucoadhesive study showed that even at the end of 8 h, 22-43 
% of microspheres were still adhering to the mucosa which shows 
that the prepared microspheres are having good mucoadhesion. The 
results are tabulated in table 3. 
 mg) using the same 
dissolution procedure as described above. A graph was plotted 
between cumulative percent drug release from optimized 
formulation and marketed formulation v/s time. The percent drug 
release per hour was studied in the same way and compared with 
optimized formulation (microspheres). 
RESULTS AND DISCUSSION 
Preparation of microspheres 
Formulation of furosemide extended-release microspheres was 
done by using ionic gelation method. With the help of optical 
microscopy, microspheres were found to be discrete, large and 
spherical, free flowing, monolithic matrix and had rigid surfaces. 
Determination of microencapsulation efficiency 
The test for encapsulation efficiency was carried out to ascertain the 
amount of drug encapsulated in microspheres. The results obtained 
are reported in table 2. From the results obtained, it can be inferred 
that there is proper distribution of Furosemide in the microspheres. 




Table 2: Microencapsulation efficiency 
Formulation Experiment Microencapsulation efficiency* (%) 
1 (1) 74.82±0.47 
2 A 78.95±1.64 
3 B 76.6±2.57 
4 Ab 84.21±0.78 
*values are mean of triplicate±SD 
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Table 3: Percentage of microspheres remained adhered after each time interval 
Formulations % mucoadhesion* of microspheres after each interval 
1 h 2 h 3 h 4 h 5 h 6 h 7 h 8 h 
1 95±0.82 88±0.51 72±0.46 52±2.13 47±0.58 32±1.85 27±0.68 22±0.56 
2 88±1.23 77±0.98 70±0.73 65±0.48 62±0.35 53±1.29 42±0.95 37±0.48 
3 90±0.67 80±2.43 75±0.39 68±0.81 53±1.58 42±0.92 38±0.46 32±0.35 
4 95±0.95 78±1.66 72±0.65 67±0.53 60±0.88 55±0.48 47±0.62 43±0.80 
*
 
In vitro drug release rate studies 
The in vitro release rate studies were performed in phosphate buffer 
media. Microspheres equivalent to containing 40 mg drug were put 
into dissolution medium. Percentage of drug released after each time 
interval is depicted in table 4. 
Optimization of formula 
Results were expressed in average±SD (n=3) 
Results of microencapsulation efficiency, mucoadhesion study and 
release rate study with the levels of factors A and B are shown in table 5. 
From the above results in table 6, the factor A, i.e. sodium alginate 
was found more important than factor B, i.e. chitosan. So, now the 
amount of chitosan was fixed to its maximum level and the amount 
of sodium alginate was varied between minimum and maximum to 
obtained optimized formula.  
Formulation A and D were prepared earlier. Now formulation B and 
C were prepared and evaluated for optimization parameters i.e. drug 
entrapment efficiency, mucoadhesion and release rate study. Results 
of all these studies are shown in table 7. 
 
Table 4: Percent in vitro drug release after specified interval of time 
Formulation Cumulative percent drug release* after following time interval 
1 h 2 h 3 h 4 h 5 h 6 h 7 h 8 h 
1 28±0.38 44±1.42 48±0.45 57±0.75 67±1.23 76±0.78 81±0.48 89±0.13 
2 40±0.44 49±0.86 60±0.73 69±0.91 79±0.84 83±0.45 87±0.59 93±0.67 
3 26±0.72 40±1.23 45±0.51 54±0.88 64±1.06 71±0.69 77±1.18 85±0.79 
4 38±0.41 45±0.65 57±0.81 67±0.7 72±0.52 79±0.57 84±0.93 89±1.08 
*
 
n=3, average of three determinations±SD 
Table 5: Results of entrapment efficiency, percent mucoadhesion, and percent drug release after 8 h 












* Cumulative % drug 
release
 
after 8 h * after 8 h  
(1) 0.5 (-) 0.5 % (-) + 74.82±0.47 22±0.56 89±0.13 
A 2.0 (+) 0.5 % (-) - 78.95±1.64 37±0.48 93±0.67 
B 0.5 (-) 1.0 % (+) - 76.6±2.57 32±0.35 85±0.79 
Ab 2.0 (+) 1.0 % (+) + 84.21±0.78 43±0.80 89±1.08 
*
 
n=3, average of three determinations±SD 
Table 6: The magnitude of the interaction between different parameters 
Effect of factor based on microencapsulation 
efficiency 
Effect of factor based on 
mucoadhesion 
Effect of factor based on drug release 
study 
Effect of factor A Effect of factor B Effect of factor A Effect of factor B Effect of factor A Effect of factor B 
5.87 3.52` 13 8 4.5 -3.67 
Magnitude of interaction 
1.74 -2 –0.175 
 







% mucoadhesion*  
after 8 h * 
% drug release*  
after 8 h 
A 1 0.5 1.0 % 76.6±0.86 32±3.0 85.01±0.76 
B 1 1.0 1.0 % 75.6±2.34 38±2.5 91.37±1.25 
C 1 1.5 1.0 % 79.14±1.65 36±1.5 94.21±2.47 
D 1 2.0 1.0 % 84.21±0.58 43±2.0 89.35±1.63 
*
 
n=3, average of three determinations±SD 
Percent release of formulation B was found better than other 
formulations after each interval of time. Microencapsulation 
efficiency of formulation B was less, but mucoadhesion was good 
as compared to other formulations.  
Microspheres prepared according to formulation B were regular 
in shape and almost spherical. So, formulation B was found to be 
optimized formulation. It was further evaluated for remaining 
parameters. 
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Compatibility study 
Compatibility study of drug and excipients was determined by using 
Differential Scanning Calorimetry apparatus Q 10. As demonstrated 
in the graphs, furosemide exhibited a characteristic, sharp 
exothermic peak at 222.28 °C which was associated with an initial 
and small melting point followed by a sharp decomposition peak of 
the drug. The alginate polymer showed wide endothermic pick at 
116 °C that indicates glass Transition Temperature (Tg) point of 
polymer and decomposition peak at about 301 ºC. DSC analysis of 
chitosan showed a broad endothermic peak at about 86.76 °C. In 
DSC graph of optimized formulation B the characteristics peak of 
furosemide was almost unchanged indicating the absence of strong 
interactions between the components and suggesting drug-
excipients compatibility in all the formulations examined. DSC 
graphs obtained for furosemide, sodium alginate, chitosan and 
optimized formulation for compatibility study are shown in fig. 1 
(A), (B), (C) and (D) respectively.  
 
 
Fig. 1: DSC graphs obtained for furosemide (A), sodium alginate (B), chitosan (C) and optimized formulation (D) 
 
Stability study 
Stability studies for the furosemide encapsulated beads and 
microspheres did not show any significant changes in their 
properties after the end of one month. No change in drug 
appearance, drug content and dissolution results were observed 
after storage of optimized formulation at 40 °C/75 % R. H. for one 
month. 
Shape and size analysis 
Optimized formulation (B) was evaluated for shape and size analysis 
with the help of optical microscopy. Drug-loaded microspheres were 
found to be discrete, large, spherical, free flowing, monolithic matrix 
and had smooth surfaces. The size of microspheres was found to be 
in the range of 692 to 815 µm. The average size of microspheres was 
found 766 µm. 
Swelling index study 
Swelling increases with time because polymer gradually absorbs 
water due to its hydrophilicity. The outer layer of the polymer 
hydrates, swells, and a gel barrier is formed at the outer surface. The 
adhesive and cohesive properties of mucoadhesive polymers are 
generally affected by their swelling behavior. The percent swelling of 
the Optimized formulation (B) was found to be 308 %.  
Plotting of release data in various models 
Based on R2 values Hixson-Crowell plot has greater R2 value, i.e. 0.992. 
So the release follows Hixson-Crowell model. The significance of this 
model is that the dissolution occurs in planes which is parallel to drug 
surface if the dimension of dosage form diminish proportionality, in 
such a manner that the initial geometry form keeps constant all the 
time. R2 values of different plots are shown in table 8. 
Comparison of release rate studies with marketed formulation 
Dissolution studies were performed for a marketed immediate 
release tablet formulation (Lasix, 40®
A comparison of optimized mucoadhesive microspheres formulation 
of furosemide with conventional release marketed formulation 
(Lasix, 40
 mg) using the same 
dissolution procedure as described above. The comparative 
dissolution profile of marketed immediate release (Lasix) and best 
formulation (B) is tabulated in table 9. 
®
 
 mg) as shown in fig. 2 confirmed the sustained-release 
behavior of the optimized formulation. 
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 value of different plots 
R2 value of different plots 
Zero order First order Higuchi plot Hixson-Crowell Korsmeyer-Peppas 
B 0.957 0.982 0.991 0.992 0.986 
 
Table 9: Comparative dissolution profile Lasix immediate release tablet and best formulation (B) 
Time (h) 1 2 3 4 5 6 7 8 


































n=3, average of three determinations±SD 
 
Fig. 2: Comparison of release rate study between optimized 




Mucoadhesive microspheres of furosemide were prepared by the 
ionic gelation method from polymers sodium alginate and chitosan 
using 22
Microencapsulation efficiency of microspheres was found to be in 
the range of 74.82 to 84.21%. The incorporation efficiency increased 
progressively with increasing sodium alginate concentration. The 
low incorporation efficiency of alginate beads cross-linked with 
Ca
 full factorial design. The particle size of microspheres was 
determined by optical microscopy ranged from 692 to 815 μm. The 
particle size of the formulations prepared were in consonance with 
that reported by other workers, such as 718-1092 μm (Fentie et al., 
2015) [4], 827-1026 μm (Arora & Budhiraja, 2012) [7], 1025-1358 
μm (Prasad et al., 2011) [12], 726-1200 μm (Das & Senapati, 2008) 
[23] and 998-1143 μm (Singhavi et al., 2012) [24]. 
2+
The swelling index of the formulation was found 308%. Diffusion of 
the drug significantly depends on the water content of microspheres. 
As polymer chain becomes more hydrated and gel becomes more 
diluted, the disentanglement concentration may be reached (i.e. the 
critical polymer concentration below which the polymer chain 
disentangles and detaches from the gelled matrix) which result in 
swelling. Consequently, faster and greater swelling of microspheres 
might lead to increased dimension of microspheres resulting to an 
increasing diffusion pathway and thus, a reduction in diffusion rate. 
So, the drug release was found to be high initially and then gradually 
decreased. 
could be attributed to the formation of porous beads ensuring 
the diffusion of the drug out of the beads at the time of curing. The 
result was similar to that reported by Das & Senapati, (2008) [23] 
and Singhavi et al., (2012) [24]. 
In vitro mucoadhesion of the microspheres was tested (table 3). 
Microspheres with a high concentration of chitosan and sodium 
alginate showed more adherences (43% after 8 h) to gastric mucosa, 
indicating that chitosan and sodium alginate provided gastric 
adherence, due to the strong electrostatic attraction between the 
polymers and the mucus glycoproteins. The result was similar to 
that reported by Singhavi et al., (2012) [24]. 
It was found that there was a decrease in drug release with an 
increase in mucoadhesive polymer content. This could be attributed 
to the greater degree of swelling upon hydration with greater 
mucoadhesive polymer content in the microspheres which leads to 
increase in the diffusional path length that slows down drug release. 
The principle of gelation or crosslinking of sodium alginate with 
CaCl2 is based on the formation of a tight junction between the 
glucuronic acid residues. The number of apparent cross-linking 
points formed with calcium alginate gel beads increased with 
increasing alginate concentration in the formulation. The increase in 
the apparent crosslinking density delayed the alginate gel 
disintegration in phosphate buffer due to the retardation of 
Ca2+exchange with Na+
The in vitro dissolution data were analyzed by different kinetic 
models in order to find out the R
and eventually caused an increase in 
microencapsulation efficiency and sustained percent drug release. 
Marketed preparation (Lasix) released 87.48 % drug in 1 h whereas 
optimized formulation released 91.37% of the drug in 8 h. The 
dissolution profile of marketed and optimized formulations showed 
the immediate and sustained release of drug respectively. Our 
results are in agreement with the reports of Fentie et al., (2015) [4]; 
Arora & Budhiraja, (2012) [7]; Marina et al., (2012) [14] and Das & 
Senapati, (2008) [23]. 
2 value, which describes the drug 
release mechanism. The values of coefficient of correlation (R2) 
obtained for the respective model are listed in table 8. In this case, 
data fitted best to the Hixson–Crowell model (R2
CONCLUSION 
= 0.992), that 
describes the drug releases by dissolution mechanism that occurs 
upon a change in surface area and diameter of particles (Lima et al., 
2015) [25]. 
Gastroretentive mucoadhesive microspheres of furosemide with 
good mucoadhesive strength could be successfully prepared by ionic 
gelatin method using sodium alginate and chitosan as polymer. This 
method was simple, reproducible and produced microspheres of 
regular shape and size. In vitro release studies indicated that there 
was a slow and sustained release of drug for all the formulations. 
Among all the formulations, formulation B microspheres showed the 
good microencapsulation efficiency, higher mucoadhesive strength 
and in vitro drug release. The size of microspheres was found to be 
in the range of 692 µm to 815 µm. The percent swelling of 
microspheres was found to be 308 %. The kinetic studies suggested 
that the drug was released by Hixson-Crowell model. The selected 
formulation B was found to be stable during the accelerated stability 
studies. Thus, the mucoadhesive gastro retentive microspheres of a 
furosemide present potential drug delivery system for improvement 
of oral bioavailability of this drug. 
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